NDAORALTABLET
Approved
Oct 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
XANAX (alprazolam) by Viatris (2) is 1,4 benzodiazepine. First approved in 1981.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XANAX (alprazolam) is an oral benzodiazepine approved in 1981 for acute treatment of generalized anxiety disorder and panic disorder. It works by binding to GABA-A receptors and enhancing GABAergic synaptic inhibition in the brain. Peak plasma levels occur 1–2 hours post-dose, with a mean half-life of 11.2 hours in healthy adults.
$0.014BPart D
LOE ApproachingAs LOE approaches, brand teams are likely consolidating and shifting focus to managed care, compliance programs, and lifecycle extension strategies.
Mechanism of Action
1,4 benzodiazepine. Alprazolam exerts its effect for the acute treatment of generalized anxiety disorder and panic disorder through binding to the benzodiazepine site of gamma-aminobutyric acid-A (GABAA) receptors in the brain and enhances GABA-mediated synaptic inhibition. 12.3 Pharmacokinetics…
Worked on XANAX at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.